|
1
|
Sarkar FH, Li Y, Wang Z and Kong D:
Pancreatic cancer stem cells and EMT in drug resistance and
metastasis. Minerva Chir. 64:489–500. 2009.PubMed/NCBI
|
|
2
|
Huang RY, Wong MK, Tan TZ, Kuay KT, Ng AH,
Chung VY, Chu YS, Matsumura N, Lai HC, Lee YF, et al: An EMT
spectrum defines an anoikis-resistant and spheroidogenic
intermediate mesenchymal state that is sensitive to e-cadherin
restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell
Death Dis. 4:e9152013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Yakubov B, Chen L, Belkin AM, Zhang S,
Chelladurai B, Zhang ZY and Matei D: Small molecule inhibitors
target the tissue transglutaminase and fibronectin interaction.
PLoS One. 9:e892852014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kumar A, Xu J, Brady S, Gao H, Yu D,
Reuben J and Mehta K: Tissue transglutaminase promotes drug
resistance and invasion by inducing mesenchymal transition in
mammary epithelial cells. PLoS One. 5:e133902010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hwang JY, Mangala LS, Fok JY, Lin YG,
Merritt WM, Spannuth WA, Nick AM, Fiterman DJ, VivasMejia PE,
Deavers MT, et al: Clinical and biological significance of tissue
transglutaminase in ovarian carcinoma. Cancer Res. 68:5849–5858.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Han HD, Mora EM, Roh JW, Nishimura M, Lee
SJ, Stone RL, BarEli M, LopezBerestein G and Sood AK: Chitosan
hydrogel for localized gene silencing. Cancer Biol Ther.
11:839–845. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shao M, Cao L, Shen C, Satpathy M,
Chelladurai B, Bigsby RM, Nakshatri H and Matei D:
Epithelial-to-mesenchymal transition and ovarian tumor progression
induced by tissue transglutaminase. Cancer Res. 69:9192–9201. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Nelson CM, Khauv D, Bissell MJ and Radisky
DC: Change in cell shape is required for matrix
metalloproteinase-induced epithelial-mesenchymal transition of
mammary epithelial cells. J Cell Biochem. 105:25–33. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Xie L, Law BK, Chytil AM, Brown KA, Aakre
ME and Moses HL: Activation of the Erk pathway is required for
TGF-beta1-induced EMT in vitro. Neoplasia. 6:603–610. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang J and Weinberg RA:
Epithelial-mesenchymal transition: At the crossroads of development
and tumor metastasis. Dev Cell. 14:818–829. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Christiansen JJ and Rajasekaran AK:
Reassessing epithelial to mesenchymal transition as a prerequisite
for carcinoma invasion and metastasis. Cancer Res. 66:8319–8326.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Oakes SR, Vaillant F, Lim E, Lee L,
Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, et al:
Sensitization of BCL-2-expressing breast tumors to chemotherapy by
the BH3 mimetic ABT-737. Proc Natl Acad Sci USA. 109:2766–2771.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nehmé A, Varadarajan P, Sellakumar G,
Gerhold M, Niedner H, Zhang Q, Lin X and Christen RD: Modulation of
docetaxel-induced apoptosis and cell cycle arrest by
all-trans retinoic acid in prostate cancer cells. Br J
Cancer. 84:1571–1576. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Emi M, Kim R, Tanabe K, Uchida Y and Toge
T: Targeted therapy against Bcl-2-related proteins in breast cancer
cells. Breast Cancer Res. 7:R940–R952. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mhaidat NM, Wang Y, Kiejda KA, Zhang XD
and Hersey P: Docetaxel-induced apoptosis in melanoma cells is
dependent on activation of caspase-2. Mol Cancer Ther. 6:752–761.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cho SY, Jeong EM, Lee JH, Kim HJ, Lim J,
Kim CW, Shin DM, Jeon JH, Choi K and Kim IG: Doxorubicin induces
the persistent activation of intracellular transglutaminase 2 that
protects from cell death. Mol Cells. 33:235–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kim SJ, Kim KH, Ahn ER, Yoo BC and Kim SY:
Depletion of cathepsin D by transglutaminase 2 through protein
cross-linking promotes cell survival. Amino Acids. 44:73–80. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Maioli E, Torricelli C and Valacchi G:
Rottlerin and cancer: Novel evidence and mechanisms.
ScientificWorldJournal. 2012:3508262012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Meerloo J, Kaspers GJ and Cloos J:
Cell sensitivity assays: The MTT assay. Methods Mol Biol.
731:237–245. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Assi J, Srivastava G, Matta A, Chang MC,
Walfish PG and Ralhan R: Transglutaminase 2 overexpression in tumor
stroma identifies invasive ductal carcinomas of breast at high risk
of recurrence. PLoS One. 8:e744372013. View Article : Google Scholar : PubMed/NCBI
|
